Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Jericho Sciences LLC
Profile last edited on: 1/11/18      CAGE: 5MK27      UEI: L6BKKLKD3MW3

Business Identifier: Antiviral therapeutic for treating HIV.
Year Founded
2009
First Award
2010
Latest Award
2018
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

7934 Lobelia Lane
Springfield, VA 22152
   (703) 862-1700
   N/A
   www.jerichosciences.com
Location: Single
Congr. District: 11
County: Fairfax

Public Profile

Jericho Sciences is working to advance scientific technologies and therapeutics to improve human health. Their primary focus is clinical development of an antiviral therapeutic for treating HIV. The candidate therapy has demonstrated significant long term virus suppression in lentivirus models. The therapy works by targeting a retrovirus protein critical to controlling HIV-1.

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
2
Conversion Rate
66.67%
Phase I Dollars
$1,010,897
Phase II Dollars
$2,385,435
Total Awarded
$3,396,332

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2018 2 NIH $2,481,902
Project Title: FIV Testing of a CNS-Relevant Antiretroviral Compound
2016 1 NIH $416,402
Project Title: Standardizable Whole Blood Culture for Evaluating HIV Eradication Strategies
2011 2 NIH $498,028
Project Title: A Novel Cns-Penetrable Antiretroviral

Key People / Management

  Heidi A Kay -- CEO

Company News

Jan 02 2012
HIV among targets: Jericho Sciences bio-startup chooses Nashville as home